Thyroid Cancer

• RET/PTC Rearrangements in Papillary Thyroid Cancer: The RET (REarranged during Transfection) proto-oncogene undergoes chromosomal translocations with various partner genes, most commonly creating RET/PTC1 (pairing with CCDC6) and RET/PTC3 (pairing with NCOA4) fusion proteins. These fusion oncoproteins constitutively activate RET tyrosine kinase signaling independent of ligand binding, driving continuous mitogenic and anti-apoptotic signals through downstream MAPK/ERK and PI3K/AKT cascades. RET/PTC rearrangements occur in 20-50% of papillary carcinomas and are particularly associated with radiation-induced thyroid cancer, as demonstrated by increased prevalence in Chernobyl survivors. This mechanism explains the frequent multifocality and early lymph node metastases observed in papillary cancers, as RET/PTC fusion is sufficient for malignant transformation even in early stages.

• BRAF V600E Mutation in Aggressive Papillary Thyroid Cancer: The BRAF V600E point mutation (valine-to-glutamic acid substitution at codon 600) occurs in approximately 40-45% of papillary thyroid carcinomas and represents one of the most significant molecular predictors of aggressive disease. This mutation results in constitutive activation of BRAF serine/threonine kinase within the MAPK pathway, leading to sustained ERK1/2 phosphorylation and driving uncontrolled cellular proliferation, reduced apoptosis, and enhanced invasiveness. BRAF V600E-positive tumors demonstrate significantly higher rates of extrathyroidal extension, lymph node metastasis, and recurrence compared to BRAF wild-type cancers; consequently, BRAF mutation status is increasingly incorporated into risk stratification algorithms and treatment intensity decisions. The presence of BRAF V600E also predicts resistance to conventional radioactive iodine therapy, as it impairs expression of the sodium-iodide symporter (NIS) necessary for iodine uptake and retention.

• PIK3CA Mutations and the PI3K/AKT/mTOR Pathway: Activating mutations in PIK3CA (encoding the p110α catalytic subunit of phosphatidylinositol 3-kinase) occur in 15-25% of follicular and papillary carcinomas and result in hyperactivation of the PI3K/AKT/mTOR survival and proliferation pathway. These mutations promote cell survival signaling by enhancing AKT phosphorylation, which inactivates pro-apoptotic proteins (BAD, FoxO) and activates anti-apoptotic molecules (MDM2, which inhibits p53). PIK3CA mutations frequently co-occur with RAS mutations and PTEN loss, creating cooperative oncogenic effects. The upregulation of mTOR signaling through this pathway supports increased protein synthesis and glucose metabolism to fuel malignant cell growth, and this axis has become a therapeutic target for mTOR inhibitors in advanced disease.

• RAS Mutations in Follicular Differentiated Thyroid Cancers: Point mutations in NRAS, KRAS, or HRAS (collectively activating RAS GTPases) are found in 20-30% of follicular adenomas, 20-40% of follicular carcinomas, and 10-20% of papillary carcinomas. These mutations lock RAS in its active GTP-bound state, constitutively stimulating downstream MAPK and PI3K pathways without requiring upstream receptor activation. RAS mutations are particularly enriched in older patients and are associated with increased invasion and distant metastases. Unlike RET/PTC rearrangements, RAS mutations are rarely associated with radiation exposure and are believed to represent spontaneous acquired events during normal aging.

• TP53 Mutations and Anaplastic Transformation: The tumor suppressor gene p53 functions as the "guardian of the genome," mediating cell cycle arrest, apoptosis, and DNA repair in response to cellular stress. Loss-of-function mutations or deletions of TP53 occur in <5% of papillary and follicular carcinomas but are present in 50-80% of anaplastic thyroid cancers. In the two-hit model of tumor suppression, loss of both TP53 alleles (typically one inherited mutation plus one acquired somatic mutation in familial cases, or biallelic somatic mutations in sporadic cases) results in complete loss of p53-mediated checkpoint control. This allows accumulation of additional mutations, unlimited proliferation, and the high-grade, rapidly progressive phenotype characteristic of anaplastic cancer. p53 loss often co-occurs with BRAF V600E or RAS mutations, and this combination drives the transition from differentiated to undifferentiated malignancy.

• RET Point Mutations in Medullary Thyroid Cancer: Medullary thyroid cancer arises from parafollicular C cells that produce calcitonin and originates uniquely from germline activating mutations in the RET proto-oncogene in approximately 50% of cases (hereditary medullary thyroid cancer, often as part of MEN 2 syndromes). Conversely, ~50% of sporadic MTC cases acquire somatic RET mutations during the patient's lifetime. Unlike RET/PTC fusions in papillary cancer, RET point mutations (most commonly in the tyrosine kinase domain) result in constitutive kinase activation with autocrine signaling. The pathophysiology of medullary cancer is dominated by continuous RET-driven MAPK and PI3K pathway activation, leading to unchecked proliferation of calcitonin-producing cells with propensity for early cervical lymph node metastases and distant hematogenous spread.

• TERT Promoter Mutations in Advanced Disease: Mutations in the promoter region of TELOMERASE REVERSE TRANSCRIPTASE (TERT), occurring in 20-30% of papillary, 20-40% of follicular, and >70% of anaplastic carcinomas, represent an alternative mechanism for overcoming replicative senescence. These mutations create novel transcription factor binding sites that increase TERT expression, thereby enabling unlimited replicative potential—a hallmark of malignancy. TERT promoter mutations are associated with older age at diagnosis, larger tumors, extrathyroidal extension, and distant metastases, making them a prognostic marker for aggressive behavior independent of histologic type.

• Ionizing Radiation Exposure: Radiation is the most well-established environmental risk factor for thyroid cancer, with a clear dose-response relationship demonstrated in atomic bomb survivors (Hiroshima/Nagasaki), patients treated with head/neck/chest radiation for benign or malignant conditions, and Chernobyl accident survivors. The latency period is typically 5-40 years, with peak incidence 15-25 years after exposure. Children exposed before age 5 have the highest relative risk (up to 100-fold), and females are 2-3 times more likely than males to develop radiation-induced thyroid cancer. Radiation preferentially induces papillary carcinoma and is strongly associated with RET/PTC rearrangements. The threshold for increased risk begins at absorbed thyroid doses as low as 0.1 Gray (Gy), and risk plateaus above 10-20 Gy as cell killing predominates; therefore, moderate cumulative radiation doses (1-5 Gy) confer maximum risk.

• Pre-existing Thyroid Disease: Patients with benign thyroid nodules or goiter have modestly increased risk of harboring occult thyroid cancer, though the presence of nodularity alone does not appear to be causally carcinogenic. In contrast, thyroiditis and hyperthyroidism are not independent risk factors for malignancy. Interestingly, patients with clinical hypothyroidism from autoimmune thyroiditis do not have increased malignancy risk, though thyroid autoimmunity may coexist with thyroid cancer by chance.

• Hormonal Factors and Estrogen Exposure: Thyroid cancer is 2-3 times more common in women than in men across all age groups, and female predominance is most pronounced in reproductive-aged women (ages 20-50). Estrogen receptor expression is documented in thyroid cancers, and estrogen signaling may promote growth and proliferation of thyroid epithelial cells. Prolonged exogenous estrogen exposure through oral contraceptives and hormone replacement therapy has been inconsistently associated with increased risk in epidemiologic studies; current evidence suggests modest or no increased risk with modern lower-dose formulations, but the question remains relevant for board examinations.

• Genetic Syndromes and Hereditary Predisposition: Familial adenomatous polyposis (FAP) caused by mutations in the APC tumor suppressor gene increases thyroid cancer risk approximately 10-fold, with papillary carcinomas appearing in 1-2% of FAP patients, often as cribriform-morular variant with unique histopathology. Werner syndrome (adult progeria from WRN mutations) and Cowden syndrome (from PTEN mutations) also confer moderately increased thyroid cancer risk. Most significantly, hereditary medullary thyroid cancer syndromes including MEN 2A, MEN 2B, and familial medullary thyroid cancer (FMTC) are caused by germline RET mutations and essentially mandate prophylactic thyroidectomy in mutation carriers by adolescence to prevent medullary cancer development.

• Prior Cancer History: Patients with history of malignancy in other sites have incrementally increased risk of developing thyroid cancer, either from shared genetic predisposition (e.g., p53 mutations in Li-Fraumeni syndrome), previous radiation exposure, or carcinogenic chemotherapy agents. Breast cancer patients, for example, have demonstrable increased thyroid cancer risk attributed partly to adjuvant radiation therapy.

• Benign Thyroid Nodules and TSH Stimulation: While benign nodules themselves are not causally related to cancer development, elevated serum TSH appears to promote growth and progression of existing thyroid cancers. Thyroid-stimulating hormone acts through the TSH receptor on thyroid follicular cells to increase cAMP-dependent signaling, which promotes MAPK pathway activation—the same pathway dysregulated by oncogenic mutations. This physiologic observation has major clinical implications, as TSH suppression therapy is a cornerstone of post-operative thyroid cancer management.

• Obesity and Metabolic Factors: Obesity, insulin resistance, and metabolic syndrome have been associated with increased thyroid cancer incidence in some epidemiologic studies, possibly through insulin growth factor (IGF) signaling and chronic inflammation, though evidence is not definitive.

• Thyroid Nodule or Mass: The most common presentation is discovery of a thyroid nodule on physical examination or imaging performed for other reasons. Thyroid nodules are prevalent in 4-7% of the population on palpation and in 16-67% on ultrasound (depending on patient age and imaging resolution), but only 5-10% of palpable nodules prove malignant. Patients may report a palpable lump in the lower neck at the level of the thyroid cartilage, often noted incidentally by the patient or family member. Large nodules may cause a visible enlargement of the anterior neck. The nodule is typically firm, sometimes fixed if invaded locally, and often solitary (though multifocal disease occurs in 10-15% of papillary cancers).

• Cervical Lymphadenopathy: Regional lymph node metastases are present at diagnosis in approximately 30-50% of papillary thyroid cancers and less commonly in follicular cancers, reflecting the lymphotropic nature of differentiated thyroid malignancies. Patients may present with enlarged lymph nodes in the central compartment (levels VI-VII, surrounding the thyroid) or lateral compartment (levels I-V, along the jugular chain). Affected lymph nodes are typically firm, non-tender, and may be matted together. Central compartment involvement may go clinically undetected but is identified on careful surgical exploration or imaging.

• Dysphagia or Dyspnea: When thyroid cancers achieve significant size or invade the larynx, pharynx, or trachea, patients may develop difficulty swallowing (dysphagia), difficulty breathing (dyspnea), stridor, or voice changes from recurrent laryngeal nerve (RLN) involvement. RLN invasion results in unilateral vocal cord paralysis, manifesting as hoarseness, breathy voice quality, or chronic cough. These symptoms typically indicate locally advanced disease (Stage III or IV per TNM staging) and worsen the prognosis substantially.

• Distant Metastatic Symptoms: Approximately 10% of patients present with or develop distant metastases, most commonly to the lungs (80% of distant sites), bone (8-15%), and brain (1-5%). Pulmonary metastases may be asymptomatic and discovered on routine chest imaging, or patients may present with cough, dyspnea, or hemoptysis if nodules are large or numerous. Bone metastases are particularly common in older patients with aggressive histology and typically affect the vertebral bodies, pelvis, and long bones; patients may present with localized bone pain, pathologic fractures, or spinal cord compression. Brain metastases are rare and typically occur in the setting of widespread disseminated disease, presenting with neurologic symptoms.

• Constitutional Symptoms: While most differentiated thyroid cancers are relatively indolent, patients with anaplastic cancer or advanced disease may present with constitutional symptoms including fatigue, weight loss, night sweats, and malaise, reflecting the aggressive biology and high tumor burden.

• Hypercalcemia (Medullary Thyroid Cancer): Patients with medullary thyroid cancer may present with symptoms of hypercalcemia (polyuria, polydipsia, cognitive dysfunction, cardiac arrhythmias) due to parathyroid hormone-related peptide (PTHrP) secretion by neoplastic C cells, though true hypercalcemia is rare unless there is widespread metastatic disease.

• Diarrhea and Flushing (Medullary Thyroid Cancer): Medullary cancers frequently secrete bioactive substances including calcitonin, calcitonin gene-related peptide (CGRP), serotonin, and prostaglandins, which may cause chronic secretory diarrhea in 30% of patients and flushing episodes from serotonin and prostaglandin E2 release. These symptoms may precede diagnosis of the primary tumor and should prompt investigation.

• Asymptomatic Discovery: The majority of papillary thyroid cancers are now discovered incidentally as asymptomatic nodules on imaging performed for other indications (e.g., ultrasound for carotid disease, CT chest for lung findings, MRI for cervical spine pathology). This stage migration toward earlier detection has contributed to improved survival rates.

• Physical Examination Findings: Beyond the nodule itself, important findings include fixed, hard nodules suggesting local invasion; ipsilateral cervical lymphadenopathy; vocal cord paralysis (assessed during phonation); horner syndrome if there is superior cervical sympathetic chain involvement; and distant findings if metastatic disease is present (e.g.,

Step 1 — biochemical triage

• Serum TSH: the first test in any thyroid nodule (American Thyroid Association nodule/DTC guideline). Most cancers are euthyroid, so a normal or high TSH mandates further imaging-based workup, while a suppressed TSH suggests an autonomously functioning nodule.
• Radionuclide (I-123 or Tc-99m) scan: obtained only when TSH is low. A hot (hyperfunctioning) nodule is almost never malignant and does not require cytology; a cold nodule carries the malignancy risk and proceeds to biopsy.

Step 2 — imaging

• Neck ultrasound with cervical node survey: mandatory in every nodule. Sonographic red flags are marked hypoechogenicity, microcalcifications, irregular/infiltrative margins, taller-than-wide shape, and extrathyroidal extension. Nodes suspicious for metastasis show loss of the fatty hilum, cystic change, or punctate calcification.
• ACR TI-RADS / ATA sonographic patterns: the named systems that convert these features into a biopsy size threshold — the more suspicious the pattern, the smaller the nodule at which fine-needle aspiration (FNA) is indicated. Purely cystic and spongiform nodules generally do not need FNA.

Step 3 — tissue

• Ultrasound-guided FNA: the diagnostic test of choice, reported by the Bethesda System for Reporting Thyroid Cytopathology (categories I–VI, from nondiagnostic to malignant, each with an implied malignancy risk and management).
• Papillary: diagnosed on cytology alone — Orphan Annie eye nuclei, nuclear grooves, intranuclear pseudoinclusions, psammoma bodies.
• Follicular: FNA cannot distinguish adenoma from carcinoma, because the diagnosis requires capsular or vascular invasion on resected histology; Bethesda IV therefore proceeds to diagnostic lobectomy or molecular testing (e.g., ThyroSeq, Afirma) for indeterminate Bethesda III/IV nodules.
• Medullary: sheets of spindled/plasmacytoid cells with amyloid stroma (Congo red, apple-green birefringence); confirm with serum calcitonin and CEA, send germline RET testing, and screen for pheochromocytoma with plasma or urine metanephrines before any surgery.
• Thyroglobulin: a postoperative surveillance marker, not a diagnostic test; anti-thyroglobulin antibodies must be measured alongside it.
• Staging: AJCC TNM, uniquely using age 55 as a cut point for differentiated cancers, plus ATA risk stratification for recurrence.

Immediate concerns

• Airway assessment: anaplastic carcinoma and bulky invasive disease can obstruct the trachea; stridor demands urgent otolaryngology evaluation and often tracheostomy before oncologic therapy (ATA anaplastic thyroid cancer guideline).
• Exclude pheochromocytoma first in medullary cancer/MEN 2: unrecognized catecholamine excess causes intraoperative hypertensive crisis. Alpha blockade (phenoxybenzamine) and adrenalectomy precede thyroidectomy — a classic sequencing question.

Definitive surgery (ATA differentiated thyroid cancer guideline)

• Active surveillance: an accepted option for low-risk papillary microcarcinoma (<1 cm) without extrathyroidal extension or nodal disease.
• Lobectomy: sufficient for unifocal low-risk tumors roughly 1–4 cm confined to the thyroid with clinically negative nodes.
• Total thyroidectomy: for tumors >4 cm, gross extrathyroidal extension, nodal or distant metastases, prior head/neck irradiation, or when radioiodine will be needed. Therapeutic central and/or lateral neck dissection is done for clinically involved nodes; prophylactic lateral dissection is not.
• Medullary cancer: total thyroidectomy with central compartment dissection; germline RET carriers undergo prophylactic thyroidectomy timed by mutation risk level (earliest in MEN 2B, codon M918T).

Adjuvant therapy

• Radioactive iodine (I-131): for intermediate- and high-risk differentiated cancers, given after thyroid hormone withdrawal or recombinant human TSH (thyrotropin alfa) plus a low-iodine diet to maximize sodium-iodide symporter uptake. Useless in medullary and anaplastic cancer (no NIS expression) and blunted by BRAF V600E-driven dedifferentiation.
• Levothyroxine TSH suppression: removes the trophic TSH signal; the depth of suppression is titrated to recurrence risk and balanced against atrial fibrillation and bone loss.

Advanced/refractory disease

• Multikinase inhibitors: lenvatinib or sorafenib for progressive RAI-refractory differentiated cancer; vandetanib or cabozantinib for advanced medullary cancer.
• Targeted agents: selective RET inhibitors (selpercatinib, pralsetinib) for RET-altered tumors; dabrafenib plus trametinib for BRAF V600E anaplastic carcinoma; NTRK inhibitors for fusion-positive disease (NCCN).

Surgical complications

• Recurrent laryngeal nerve injury: the nerve runs in the tracheoesophageal groove near the inferior thyroid artery; unilateral injury causes hoarseness and a breathy voice with a paramedian cord on laryngoscopy. Bilateral injury is an airway emergency — both cords sit adducted, producing stridor and requiring reintubation or tracheostomy.
• External branch of the superior laryngeal nerve injury: cricothyroid denervation causes loss of high pitch and vocal fatigue — the singer's complication.
• Postoperative hematoma: expanding neck swelling with respiratory distress within hours of surgery. Emergency — open the wound at the bedside to decompress before imaging.
• Hypoparathyroidism: inadvertent parathyroid removal or devascularization. Perioral tingling, Chvostek and Trousseau signs, prolonged QT, tetany, or laryngospasm; symptomatic hypocalcemia is an emergency treated with IV calcium gluconate plus calcitriol.

Treatment-related

• Radioiodine toxicity: sialadenitis and xerostomia (NIS is expressed in salivary tissue), transient nausea, radiation thyroiditis, gonadal dysfunction, a small excess of second primary malignancies including leukemia, and pulmonary fibrosis when diffuse miliary lung metastases are treated.
• Iatrogenic thyrotoxicosis from TSH suppression: atrial fibrillation and accelerated bone loss, especially in older postmenopausal patients — the reason suppression depth is risk-adapted.
• Kinase inhibitor toxicity: hypertension, proteinuria, hemorrhage, fistula formation, and hand-foot syndrome with lenvatinib/sorafenib.

Disease-related

• Locoregional recurrence: signaled by a rising suppressed thyroglobulin (interpret only with anti-thyroglobulin antibodies) or by a shortening calcitonin/CEA doubling time in medullary cancer.
• Aerodigestive invasion: hemoptysis, dysphagia, or stridor from tracheal or esophageal invasion — airway compromise is an emergency.
• Skeletal metastases: osteolytic lesions causing pathologic fracture; spinal cord compression presenting with back pain and neurologic deficit is an emergency requiring dexamethasone and urgent MRI.
• Anaplastic transformation: a rapidly enlarging, fixed, hard neck mass in an older patient with long-standing goiter or prior differentiated cancer, driven by TP53 and TERT alterations.

• Single best next step for a thyroid nodule: check TSH and get a neck ultrasound — never jump straight to FNA. If TSH is suppressed, order a radionuclide scan; a hot nodule is essentially never cancer, whereas a cold nodule earns the biopsy.
• Papillary is the histology-recognition question: Orphan Annie eye nuclei, nuclear grooves, intranuclear pseudoinclusions, and psammoma bodies; it spreads by lymphatics to cervical nodes and still carries an excellent prognosis. So-called lateral aberrant thyroid tissue is metastatic papillary carcinoma in a lymph node, not ectopic normal thyroid.
• Follicular carcinoma cannot be diagnosed by FNA: cytology looks identical to a follicular adenoma because the diagnosis requires capsular or vascular invasion on the resected specimen. Follicular cancer spreads hematogenously to lung and bone, which is why a patient can present with a pathologic fracture.
• Medullary carcinoma is the neuroendocrine one: parafollicular C cells, amyloid stroma staining with Congo red, and calcitonin (plus CEA) as the tumor marker. It does not take up iodine — radioiodine is useless, and total thyroidectomy with central node dissection is the answer.
• The association examiners love: germline RET mutation → MEN 2A (MTC, pheochromocytoma, primary hyperparathyroidism) and MEN 2B (MTC, pheochromocytoma, mucosal neuromas, marfanoid habitus, no hyperparathyroidism). Always rule out and treat the pheochromocytoma before thyroid surgery.
• Anaplastic carcinoma: an elderly patient with a rock-hard, rapidly enlarging, fixed neck mass and stridor. Secure the airway first; think TP53 and TERT, and test for BRAF V600E because dabrafenib plus trametinib is an option.
• Common distractors to avoid:
• Thyroglobulin is a post-treatment surveillance marker, not a diagnostic test for a new nodule — and it is uninterpretable if anti-thyroglobulin antibodies are present.
• Most thyroid cancers are euthyroid; normal thyroid function tests never exclude malignancy.
• A history of childhood head/neck irradiation raises malignancy risk in a nodule; a history of Hashimoto thyroiditis does not.